NMI 900
Alternative Names: GSK-1070916; GSK1070916A; NMI-900Latest Information Update: 20 Jan 2023
At a glance
- Originator GlaxoSmithKline
- Developer Cancer Research UK; Nemucore Medical Innovations; Oncology Venture A/S
- Class Antineoplastics; Indoles; Methylurea compounds; Pyrazoles; Pyridines; Pyrroles; Small molecules
- Mechanism of Action Aurora kinase B inhibitors; Aurora kinase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Research Myeloid leukaemia
- No development reported Acute myeloid leukaemia; Breast cancer; Chronic myeloid leukaemia; Non-small cell lung cancer; Ovarian cancer
Most Recent Events
- 10 Dec 2022 Early research in Myeloid leukaemia in USA (IV) before December 2022
- 28 Jul 2022 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Monotherapy) in USA (IV)
- 28 Jul 2022 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy) in USA (IV)